At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Glycerinated peanut allergenic extract +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 25, 2007·Updated Aug 21, 2019
In Brief
A Phase 2 clinical trial evaluating Glycerinated peanut allergenic extract and Placebo for peanut extract (glycerin) for Food Hypersensitivity and 3 related conditions. Completed, enrolled 40 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
CountriesUnited States
CollaboratorsConsortium of Food Allergy Research
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionDec 2010
Study CompletionDec 2014
TodayJul 2026
First PostedDec 25, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.5 years ago
Interventions
Glycerinated peanut allergenic extractdrug
Glycerinated peanut extract delivered sublingually.
Placebo for peanut extract (glycerin)drug
Placebo (glycerin) delivered sublingually.